Brad Loncar
@bradloncar
#Biotech, Founder of @BiotechTV, KC native, @univmiami hurricane.🧬🙌
𝐂𝐨𝐦𝐢𝐧𝐠 𝐒𝐨𝐨𝐧: BiotechTV visited @MonteRosaTx in Boston today and spoke with @markus_warmuth about the latest in molecular glue degraders. Watch for the full episode later this afternoon.
Today I'm visiting the heads of Abivax and Monte Rosa. Let me know any questions you have about the obefazimod program or molecular glue degraders.
More transparency around FDA decisions is a good thing (as FDA commissioner @DrMakaryFDA himself has recently highlighted). In that spirit, I appreciate Replimune's CEO sharing with us the company's perspective of yesterday's CRL during a difficult time for them.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of @Replimune walks us through the program's timeline and history, and what this might mean for its future. $REPL Full video: biotechtv.com/post/sushil-pa…
𝐓𝐨𝐧𝐢𝐠𝐡𝐭: We get the company's perspective on yesterday's CRL, and consider what it might mean for oncology drug development. Please submit any questions you might have.
Headed back to Boston this morning from a short visit to NY and I have great stuff coming up over on @BiotechTV. Today I’ll be visiting Replimune, and tomorrow Abivax and Monte Rosa. Please let me know any good questions to ask. $REPL $ABVX $GLUE
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming. Full video: biotechtv.com/post/rbc-chris…
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: BiotechTV is broadcasting from the @decodingbio AI x BIO Summit at the NYSE today. Catch @RS_Flinn’s coverage all day.
I’m at the iconic NYSE today and will be speaking with Metsera’s CEO for BiotechTV. Let me know any key obesity questions to ask. Plus, RBC’s trading desk strategist, and @RS_Flinn will have a ton of AI companies for NYSE’s AI Day.
Right thing to do.
$SRPT just announced pause to all Elevidys shipments in the US.
I took a tour of @daphnezohar's new offices today in the Seaport.🐟
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @SeaportTx today and was given a tour by Founder & CEO @daphnezohar.
My goodness. $XBI
NEW: Meet Vinay Prasad: The Progressive Leftist Saboteur Undermining President Trump’s FDA The vetting crisis continues… @VPrasadMDMPH @US_FDA @RobertKennedyJr @SergioGor loomered.com/2025/07/20/mee…
If Sarepta doesn't reform itself by Monday, and if the biotech industry is serious about 1) doing the right thing and 2) preserving public trust, this should happen: 1) @Roche should publicly denounce its partner's decisions. 2) @IAmBiotech should kick Sarepta out of BIO.
Sarepta’s board should fire Doug Ingram tonight and then all resign themselves. The company needs a reset over the weekend for the sake of patients, and to preserve public trust in the biotech industry.
Third death from a Sarepta gene therapy, patient was in phase 1 trial of limb-girdle muscular dystrophy Type 2. Cause was acute liver injury. Regulators, patient advocates have been informed. biocentury.com/article/656520…
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @PrimeMedicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video: biotechtv.com/post/prime-med…
Jon's report is something I always look forward to. Chock full of data showing trends in venture deals, raises, and the IPO environment.
𝟐𝟎𝟐𝟓 𝐌𝐢𝐝-𝐘𝐞𝐚𝐫 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: Today is the day....every year at this time, @HSBCInnovation's @jonnyVChealth shares his venture healthcare report. It's out now, download the full report here: hsbcinnovationbanking.com/us/en/business… #sponsored
As FDA shares its views on policy via these FDA Direct videos, starting in August, @BiotechTV will launch a regular show called Biotech Direct. Featuring a rotating panel of industry voices discussing policy and other issues from their perspective. Filmed in person from Boston.
Our latest FDA Direct conversation covered just about everything! We talked about data transparency, publishing the FDA’s decision letters, Vinay’s work at CBER, our roundtable on hormone replacement therapy, and the importance of questioning medical dogma.
We’re about to see a shift in who takes credit for the difference between inflated list prices and what is actually paid from PBMs to the White House. The question will be how this change affects real prices and overall spending. wsj.com/health/pharma/…
